Athenex (STU:2MT0) EBIT : €-69.52 Mil (TTM As of Dec. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Athenex EBIT?

Athenex's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2022 was €-14.43 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2022 was €-69.52 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Athenex's annualized ROC % for the quarter that ended in Dec. 2022 was -40.57%. Athenex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -215.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Athenex's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -616.21%.

Athenex EBIT Historical Data

The historical data trend for Athenex's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex EBIT Chart

Athenex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-109.90

-105.45

-106.15

-133.02

-68.71

Athenex Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EBIT	Get a 7-Day Free Trial															-59.61	-23.54	-18.68	-12.88	-14.43

Competitive Comparison of Athenex's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Athenex's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Athenex's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Athenex's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Athenex's EV-to-EBIT falls into.

Athenex EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-69.52 Mil.

Athenex (STU:2MT0) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Athenex's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

	ROC % (Q: Dec. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2022 )	+	Invested Capital (Q: Dec. 2022 ))	/ count )
=	-51.564 * ( 1 - 0.99% )	/	( (131.063	+	120.626)	/ 2 )
=	-51.0535164	/	125.8445
=	-40.57 %

where

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	230.634	-	62.988	-	( 36.583	-	max(0, 85.752	-	127.973	+	36.583	))
=	131.063

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	192.628	-	62.515	-	( 29.744	-	max(0, 108.446	-	117.933	+	29.744	))
=	120.626

Note: The Operating Income data used here is four times the quarterly (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Athenex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2022		Q: Dec. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-57.724	/	( ( (8.435 + max(22.761, 0))	+	(5.705 + max(16.761, 0)) )	/	2 )
=	-57.724	/	( ( 31.196	+	22.466 )	/	2 )
=	-57.724	/	26.831
=	-215.14 %

where Working Capital is:

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(33.241	+	42.459	+	15.69)	-	(62.988	+	2.818	+	2.823)
=	22.761

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(26.305	+	40.265	+	21.619)	-	(62.515	+	2.665	+	6.248)
=	16.761

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Athenex's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2022 )
	=	-69.521	/	11.282
	=	-616.21 %

Athenex EBIT Related Terms

Thank you for viewing the detailed overview of Athenex's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Athenex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (STU:2MT0) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203

Website

https://www.athenex.com

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Athenex Headlines

No Headlines